These were not limited to markers such as p-tau217, p-tau231, p-tau181, and GFAP, the elevation of which have consistently shown strong associations with brain Aβ and/or tau load, but included novel protein targets that inform about the disease state of the individual in different pathological stages across the biological AD continuum. This evidence concerns the gene MAPT and Alzheimer disease.